Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study in to compare the efficacy of treatment of diabetic macular edema (DME) using Ranibizumab (Lucenti®), Aflibercept (Eylea®) and Aflibercept (Eylea®) plus Ranibizumab (Lucentis®).

It is a randomized clinical trial that will evaluate the efficacy of the combination of two substances currently used in the treatment of DME. Will be allocated in different four groups randomly pacients who receive treatment with intravitreal injections of ranibizumab, aflibercept or a combination of aflibercept and ranibizumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Olhos de Goiania
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion Criteria:

• patients with Diabetic macular edema

Exclusion Criteria:

• patients without diabetic macular edema, or with diabetic macular edema with other disease that can make confuse about the diagnose